Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Haiko Bloemendal"'
Autor:
Sjoerd Klaver, André Vis, Gerard Vreugdenhil, Niven Mehra, Tessa van Elst, Jean-Paul van Basten, Pieter van den Berg, Roderick van den Bergh, Sjaak Bloem, Joyce van Dodewaard-de Jong, Mathijs Hendriks, Zarina Lalmahomed, Daphne Luijendijk, Addy van de Luijtgaarden, Luc Roelofs, Eric Vrijhof, Bart Wijsman, Haiko Bloemendal, Peter Mulders
Publikováno v:
BMJ Open, Vol 13, Iss 8 (2023)
Introduction The treatment landscape for de novo metastatic hormone sensitive prostate cancer (mHSPC) is rapidly evolving. With an abundance of available treatment strategies, selecting the optimal strategy for an individual patient is becoming incre
Externí odkaz:
https://doaj.org/article/801ee6f62ee04d6d870bfa0478fe2607
Autor:
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Lonneke Timmers, Anke Pisters-van Roy, Joël Gijzen, Nicole M.A. Blijlevens, Haiko Bloemendal
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Introduction: utcome-based agreements (OBAs) are occasionally deployed to relieve the burden of high drug prices on healthcare budgets. However, it is not clear when manufacturers are willing to collaborate in establishing such agreements. Therefore,
Externí odkaz:
https://doaj.org/article/2c82add5c86d4c679c4a8eb4cffafd74
Autor:
Iris S. H. Kloots, Peter H.J. Slootbeek, Minke Smits, Sjoerd van Helvert, Leonie I. Kroeze, Marleen Kets, Katrien Grünberg, Jolique van Ipenburg, Marjolijn Ligtenberg, Jack A. Schalken, Inge M. van Oort, Haiko Bloemendal, Winald R. Gerritsen, Niven Mehra
Publikováno v:
Journal of Clinical Oncology. 40:40-40
40 Background: Castration-resistant prostate cancer (CRPC) comprises distinct molecular actionable subtypes. Radboudumc, a tertiary referral center for PCa, hosts a Molecular Tumor Board (MTB), and frequently sees CRPC patients (pts) for referral for
Autor:
Haiko Bloemendal
Publikováno v:
Medische Oncologie. 23:4-4
Autor:
Joyce M. van Dodewaard-de Jong, Haiko Bloemendal, John M. H. de Klerk, Daniela E Oprea-Lager, Otto S. Hoekstra, H Pieter van den Berg, Maartje Los, Aart Beeker, Joe M. O'Sullivan, Henk M.W. Verheul, Alfonsus Johannes Maria van den Eertwegh
Publikováno v:
Journal of Clinical Oncology. 34:5081-5081
5081Background: Docetaxel is first line chemotherapy in CRPC. Re-188 is a beta-emitting radiopharmaceutical that targets bone metastases. We investigated whether treatment with docetaxel plus Re-18...
Autor:
Esther W. Bouman-Wammes, Joyce M. van Dodewaard-de Jong, Haiko Bloemendal, John M. H. de Klerk, Henk M.W. Verheul, Alfonsus Johannes Maria van den Eertwegh
Publikováno v:
Journal of Clinical Oncology. 34:e16508-e16508
e16508Background: In patients with metastatic castration resistant prostate cancer (mCRPC), bone-seeking radiopharmaceuticals such as rhenium-188-HEDP (re-188), are effective for pain palliation an...